H.C.Wainwright & Co.

H.C.Wainwright & Co. initiated coverage on Kadmon Holdings Inc (NYSE: KDMN) with a Buy rating and a price tag of $25, citing varied clinical pipeline. Analysts led by Andrew Fein categorized biotech firms into three sections. The first category belonged to those that have proven track record,...